Parmax Pharma Ltd — Board Meeting, 03-06-2026: Board Meeting
03-06-2026 | 06:43 pm
03-06-2026 | 06:43 pm
Parmax Pharma's Board met and approved financial results for Q4 & FY26. For the quarter, Revenue from operations was Rs 3.31 Cr and Net Loss Rs 0.58 Cr. For the financial year, Revenue was Rs 12.11 Cr, with a Net Loss of Rs 4.16 Cr.
No comments yet. Be the first to comment!
